TPWA
TVTX icon

Twin Peaks Wealth Advisors’s Travere Therapeutics TVTX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$594 Buy
+20
New +$598 ﹤0.01% 2005
2025
Q3 		– Sell
-1
Closed -$17 – 1983
2025
Q2 		$17 Buy
+1
New +$17 ﹤0.01% 2256

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Twin Peaks Wealth Advisors's TVTX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 20 shares worth $594. The stake represents ﹤0.01% of the portfolio and ranks #2005 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in TVTX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in TVTX in Q2 2025 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 20 shares of Travere Therapeutics worth $594 as of Q1 2026.
  • Travere Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2005 holding.
  • Twin Peaks Wealth Advisors first reported a position in Travere Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.